Oakworth Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $511K | Buy |
18,181
+1,492
| +9% | +$39.7K | 0.03% | 139 |
|
|
2025
Q4 | $416K | Sell |
16,689
-699
| -4% | -$17.6K | 0.02% | 149 |
|
|
2025
Q3 | $443K | Sell |
17,388
-63
| -0.4% | -$1.55K | 0.03% | 147 |
|
|
2025
Q2 | $423K | Sell |
17,451
-8,609
| -33% | -$201K | 0.03% | 137 |
|
|
2025
Q1 | $660K | Sell |
26,060
-2,595
| -9% | -$67.9K | 0.05% | 107 |
|
|
2024
Q4 | $760K | Sell |
28,655
-36,441
| -56% | -$988K | 0.05% | 100 |
|
|
2024
Q3 | $1.88M | Sell |
65,096
-2,009
| -3% | -$58.6K | 0.13% | 52 |
|
|
2024
Q2 | $1.88M | Sell |
67,105
-1,140
| -2% | -$31.4K | 0.14% | 52 |
|
|
2024
Q1 | $1.89M | Buy |
68,245
+7,713
| +13% | +$214K | 0.14% | 50 |
|
|
2023
Q4 | $1.74M | Sell |
60,532
-16,010
| -21% | -$484K | 0.14% | 50 |
|
|
2023
Q3 | $2.54M | Sell |
76,542
-644
| -0.8% | -$22.8K | 0.23% | 35 |
|
|
2023
Q2 | $2.83M | Buy |
77,186
+533
| +0.7% | +$20.7K | 0.24% | 29 |
|
|
2023
Q1 | $3.13M | Buy |
76,653
+1,433
| +2% | +$61.9K | 0.28% | 28 |
|
|
2022
Q4 | $3.85M | Sell |
75,220
-1,293
| -2% | -$62K | 0.37% | 22 |
|
|
2022
Q3 | $3.35M | Sell |
76,513
-40
| -0.1% | -$1.94K | 0.37% | 26 |
|
|
2022
Q2 | $4.01M | Buy |
76,553
+651
| +0.9% | +$33.2K | 0.4% | 26 |
|
|
2022
Q1 | $3.93M | Buy |
75,902
+1,563
| +2% | +$81.1K | 0.34% | 27 |
|
|
2021
Q4 | $4.39M | Sell |
74,339
-2,794
| -4% | -$138K | 0.37% | 26 |
|
|
2021
Q3 | $3.32M | Sell |
77,133
-2,971
| -4% | -$132K | 0.32% | 27 |
|
|
2021
Q2 | $3.14M | Sell |
80,104
-6,075
| -7% | -$236K | 0.31% | 25 |
|
|
2021
Q1 | $3.12M | Sell |
86,179
-9,342
| -10% | -$332K | 0.35% | 25 |
|
|
2020
Q4 | $3.52M | Sell |
95,521
-7,930
| -8% | -$291K | 0.46% | 22 |
|
|
2020
Q3 | $3.6M | Buy |
103,451
+614
| +0.6% | +$21.5K | 0.58% | 21 |
|
|
2020
Q2 | $3.19M | Sell |
102,837
-2,293
| -2% | -$77.9K | 0.57% | 22 |
|
|
2020
Q1 | $3.26M | Sell |
105,130
-8,466
| -7% | -$288K | 0.76% | 19 |
|
|
2019
Q4 | $4.21M | Sell |
113,596
-2,316
| -2% | -$82.5K | 0.74% | 22 |
|
|
2019
Q3 | $3.95M | Sell |
115,912
-3,470
| -3% | -$126K | 0.77% | 23 |
|
|
2019
Q2 | $4.91M | Sell |
119,382
-1,451
| -1% | -$57.6K | 0.94% | 21 |
|
|
2019
Q1 | $4.87M | Sell |
120,833
-19,497
| -14% | -$781K | 1% | 20 |
|
|
2018
Q4 | $5.81M | Buy |
140,330
+252
| +0.2% | +$10.5K | 1.32% | 17 |
|
|
2018
Q3 | $5.86M | Sell |
140,078
-62,712
| -31% | -$2.41M | 1.17% | 17 |
|
|
2018
Q2 | $6.98M | Sell |
202,790
-14,857
| -7% | -$508K | 1.45% | 16 |
|
|
2018
Q1 | $7.56M | Sell |
217,647
-556
| -0.3% | -$19.1K | 1.81% | 13 |
|
|
2017
Q4 | $7.5M | Buy |
218,203
+2,902
| +1% | +$99K | 1.77% | 13 |
|
|
2017
Q3 | $6.93M | Buy |
215,301
+6,718
| +3% | +$216K | 1.78% | 14 |
|
|
2017
Q2 | $6.65M | Buy |
208,583
+6,449
| +3% | +$203K | 1.82% | 13 |
|
|
2017
Q1 | $6.56M | Buy |
202,134
+25,994
| +15% | +$820K | 1.9% | 13 |
|
|
2016
Q4 | $5.37M | Buy |
176,140
+6,185
| +4% | +$189K | 1.77% | 12 |
|
|
2016
Q3 | $5.46M | Buy |
169,955
+20,108
| +13% | +$672K | 1.89% | 12 |
|
|
2016
Q2 | $4.93M | Buy |
149,847
+9,166
| +7% | +$293K | 1.85% | 12 |
|
|
2016
Q1 | $3.96M | Buy |
140,681
+703
| +0.5% | +$20.1K | 1.58% | 12 |
|
|
2015
Q4 | $4.29M | Buy |
139,978
+15,673
| +13% | +$493K | 1.78% | 11 |
|
|
2015
Q3 | $3.7M | Buy |
124,305
+30,007
| +32% | +$962K | 1.95% | 10 |
|
|
2015
Q2 | $3.23M | Buy |
94,298
+4,508
| +5% | +$147K | 1.53% | 12 |
|
|
2015
Q1 | $2.89M | Buy |
89,790
+4,968
| +6% | +$158K | 1.34% | 15 |
|
|
2014
Q4 | $2.51M | Sell |
84,822
-376
| -0.4% | -$10.8K | 1.3% | 17 |
|
|
2014
Q3 | $2.38M | Buy |
85,198
+1,510
| +2% | +$42.4K | 1.39% | 16 |
|
|
2014
Q2 | $2.36M | Buy |
83,688
+2,869
| +4% | +$81.8K | 1.43% | 17 |
|
|
2014
Q1 | $2.46M | Buy |
80,819
+3,051
| +4% | +$91K | 1.61% | 15 |
|
|
2013
Q4 | $2.26M | Buy |
+77,768
| New | +$2.26M | 1.6% | 18 |
|
Other funds holding PFE
VCM
VPM
Oakworth Capital's PFE Position: Q1 2026 in Review
Oakworth Capital increased its Pfizer (PFE) stake by 8.9% in Q1 2026, buying an estimated $39.7K and bringing the position to 18,181 shares worth $511K. The position accounts for 0.03% of the portfolio, ranked #139.
Oakworth Capital first reported a position in PFE in Q4 2013 and has held it in 50 quarters since. The position peaked at $7.56M in Q1 2018. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Oakworth Capital held 18,181 shares of Pfizer worth $511K as of Q1 2026.
- Oakworth Capital bought 1,492 Pfizer shares in Q1 2026, an estimated $39.7K.
- Pfizer made up 0.03% of Oakworth Capital's portfolio in Q1 2026, its #139 holding.
- Oakworth Capital first reported a position in Pfizer in Q4 2013 and has held it in 50 quarters since.
- Oakworth Capital's Pfizer position peaked at $7.56M in Q1 2018.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Oakworth Capital's 13F filing for Q1 2026, filed 24 Apr 2026.